A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Clinical trial NCT04967248 · TERMINATED

Trial details

NCT number

NCT04967248

Sponsor

Novartis Pharmaceuticals

Status

TERMINATED

Study type

OBSERVATIONAL

Start date

2023-06-21

Primary completion

2024-10-18

Enrollment

4

View on ClinicalTrials.gov